Glaucoma Biomarkers

Inclusion criteria

• Either gender.
• Any self-declared ethnoracial category.
• Greater than or equal to 40 years.
• Healthy eyes with the crystalline lens, without glaucoma (cup:disc ratio < 0.8 both eyes; asymmetry of cup:disc ratio between eyes < 0.2).
• Open angles.
• Ability to cooperate for aqueous humor dynamic studies.
• Nonprescription and prescription topical ophthalmic products and systemic medications other than those mentioned in the exclusion criteria will be allowed during the study.
• Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session.
• Able to participate on site over the multi-visit study period.

Exclusion criteria

• Women who are pregnant due to IOP changes.
• Any form of glaucoma, including extremely narrow angle with complete or partial closure.
• Current use of any glaucoma medication, either topically or orally.
• Chronic or recurrent inflammatory eye disease.
• Ocular trauma within the past 6 months.
• Ocular infection or ocular inflammation in the past 3 months.
• Clinically significant retinal disease.
• Any abnormality preventing reliable fluorophotometry of either eye, such as corneal scarring or severe dry eye that results in punctate fluorescein staining of the cornea.
• Intraocular surgery within 6 months.
• Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.
• Subjects must be on a stable regimen for at least 30 days prior to the Visit 1 regarding a chronic systemic medication that may affect IOP (i.e., sympathomimetic agents, beta-blockers, alpha-adrenergic agonists, alpha-adrenergic blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, etc.). Any change of such medication during the study period will result in exclusion.
• Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.